Decision

Early access to medicines scheme (EAMS) scientific opinion: Dupilumab for treatment of dermatitis

This publication was withdrawn on

Withdrawn as this product received a marketing authorisation from the European Commission.

EAMS scientific opinion given to Dupilumab to treat adult patients with severe atopic dermatitis, including the public assessment report.